Stockholm - Free Realtime Quote SEK

Alligator Bioscience AB (publ) (ATORX.ST)

Compare
0.5810 -0.0330 (-5.37%)
As of 4:32 PM GMT+1. Market Open.
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for ATORX.ST

Recent News: ATORX.ST

View More
First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial

First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial
ACCESSWIRE 8 days ago
Alligator Bioscience Presents an Update with Clinical and Biomarker Results with Mitazalimab in Phase 2 Pancreatic Cancer at SITC 2024

Alligator Bioscience Presents an Update with Clinical and Biomarker Results with Mitazalimab in Phase 2 Pancreatic Cancer at SITC 2024
ACCESSWIRE 13 days ago
Nomination Committee Appointed in Respect of AGM 2025 in Alligator Bioscience AB

Nomination Committee Appointed in Respect of AGM 2025 in Alligator Bioscience AB
ACCESSWIRE 19 days ago
Alligator Bioscience to Participate in Upcoming Scientific and Investor Conferences in Q4 2024

Alligator Bioscience to Participate in Upcoming Scientific and Investor Conferences in Q4 2024
ACCESSWIRE 20 days ago
Alligator Bioscience and Aptevo Therapeutics to Present Additional Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at SITC 2024

Alligator Bioscience and Aptevo Therapeutics to Present Additional Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at SITC 2024
ACCESSWIRE 21 days ago
Alligator Bioscience AB Reports Financial Results for the First 9 Months of 2024 and for Q3 2024 and Provides a Business Update

Alligator Bioscience AB Reports Financial Results for the First 9 Months of 2024 and for Q3 2024 and Provides a Business Update
ACCESSWIRE 26 days ago

Alligator Bioscience AB (FRA:7AL) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ...
GuruFocus.com last month
Alligator Bioscience and Aptevo Therapeutics Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study

Alligator Bioscience and Aptevo Therapeutics Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study
ACCESSWIRE 2 months ago
Alligator Bioscience and Aptevo Therapeutics to Present Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types at ESMO Congress 2024

Alligator Bioscience and Aptevo Therapeutics to Present Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types at ESMO Congress 2024
ACCESSWIRE 2 months ago
Alligator Bioscience AB Reports Financial Results for H1 2024 and Q2 2024 and Provides a Business Update

Alligator Bioscience AB Reports Financial Results for H1 2024 and Q2 2024 and Provides a Business Update
ACCESSWIRE 4 months ago
Alligator Bioscience Announces Substantial Overall Survival Benefit and Unprecedented Duration of Response in the 18-Month Analysis from Mitazalimab OPTIMIZE-1 Phase 2 Study in 1st Line Pancreatic Cancer

Alligator Bioscience Announces Substantial Overall Survival Benefit and Unprecedented Duration of Response in the 18-Month Analysis from Mitazalimab OPTIMIZE-1 Phase 2 Study in 1st Line Pancreatic Cancer
ACCESSWIRE 4 months ago
View More

Related Tickers

CANTA.ST Cantargia AB (publ)
1.8430
-1.55%
 
VICO.ST Vicore Pharma Holding AB (publ)
7.51
-1.44%
 
MEB.F MedinCell S.A.
16.38
-3.08%
 
AELIS.PA Aelis Farma SA
2.9200
-0.68%
 
ACE.ST Ascelia Pharma AB (publ)
2.6750
-3.08%
 
HRTIS.HE Herantis Pharma Oyj
1.2500
+2.46%
 
ADOC.PA Adocia SA
8.26
+0.24%
 
ALSEN.PA Sensorion SA
0.6800
+0.59%
 
ABNX.PA ABIONYX Pharma SA
1.3220
-0.15%
 
HPHA.DE Heidelberg Pharma AG
2.3200
+1.75%